Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Beam Therapeutics Inc. (BEAM)

30.39   0.05 (0.16%) 03-24 16:00
Open: 30.12 Pre. Close: 30.34
High: 30.83 Low: 29.59
Volume: 739,777 Market Cap: 2,324(M)

Technical analysis

as of: 2023-03-24 4:24:20 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 44.4     One year: 50.49
Support: Support1: 29.59    Support2: 24.61
Resistance: Resistance1: 38.01    Resistance2: 43.22
Pivot: 33.85
Moving Average: MA(5): 31.2     MA(20): 35.17
MA(100): 41.67     MA(250): 45.65
MACD: MACD(12,26): -2.8     Signal(9): -2.5
Stochastic oscillator: %K(14,3): 6.1     %D(3): 9.8
RSI: RSI(14): 29.9
52-week: High: 73.26  Low: 27.77
Average Vol(K): 3-Month: 916 (K)  10-Days: 1,091 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BEAM ] has closed above bottom band by 15.2%. Bollinger Bands are 6.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 30.87 - 31.05 31.05 - 31.21
Low: 29.14 - 29.36 29.36 - 29.57
Close: 30.06 - 30.39 30.39 - 30.69

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Headline News

Mon, 27 Mar 2023
William Blair Weighs in on Beam Therapeutics Inc.'s Q1 2023 ... - MarketBeat

Fri, 24 Mar 2023
Chutes & Ladders—Ex-Seagen CEO takes new role less than a year ... - FierceBiotech

Tue, 21 Mar 2023
Beam Therapeutics (NASDAQ:BEAM) Research Coverage Started ... - MarketBeat

Tue, 21 Mar 2023
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief ... - GlobeNewswire

Wed, 15 Mar 2023
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference -

Mon, 13 Mar 2023
January 2024 Options Now Available For Beam Therapeutics - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 72 (M)
Shares Float 64 (M)
% Held by Insiders 1.7 (%)
% Held by Institutions 86.5 (%)
Shares Short 12,480 (K)
Shares Short P.Month 12,420 (K)

Stock Financials

EPS -4.06
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.53
Profit Margin (%) 0
Operating Margin (%) -555.7
Return on Assets (ttm) -15.1
Return on Equity (ttm) -33.4
Qtrly Rev. Growth -60.8
Gross Profit (p.s.) -3.47
Sales Per Share 0.84
EBITDA (p.s.) -4.48
Qtrly Earnings Growth 0
Operating Cash Flow 23 (M)
Levered Free Cash Flow 138 (M)

Stock Valuations

PE Ratio -7.49
PEG Ratio -1.6
Price to Book value 2.88
Price to Sales 36.11
Price to Cash Flow 97.65

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.